Clinical Trials
96 trialsNCT07354074 2026-05-26
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Novartis
Phase 2 Recruiting
NCT05748171 2026-05-14
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
Pfizer
Phase 2 Recruiting
NCT04996875 2026-05-05
APEX
Cogent Biosciences, Inc.
Phase 2 Recruiting
NCT03578367 2026-04-21
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Novartis
Phase 2 Completed
NCT07216443 2026-04-15
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Orca Biosystems, Inc.
Phase 2 Recruiting
NCT02467270 2026-03-17
OPTIC
Takeda
Phase 2 Completed
NCT02723994 2026-03-11
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Incyte Corporation
Phase 2 Completed
NCT05479994 2026-03-04
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
BeOne Medicines
Phase 2 Active not recruiting
NCT04977024 2026-02-11
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
GeoVax, Inc.
Phase 2 Active not recruiting
NCT02337829 2026-01-08
Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL
Acerta Pharma BV
Phase 2 Completed
NCT02966756 2025-12-24
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
AbbVie
Phase 2 Recruiting
NCT06824168 2025-12-04
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
Daiichi Sankyo
Phase 2 Recruiting
NCT00777036 2025-08-29
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib
Bristol-Myers Squibb
Phase 2 Completed
NCT04305444 2025-01-08
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
Zhejiang DTRM Biopharma
Phase 2 Terminated
NCT02910583 2024-12-20
Captivate
Pharmacyclics LLC.
Phase 2 Completed
NCT01943851 2024-10-01
A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies
GlaxoSmithKline
Phase 2 Completed
NCT02000427 2024-05-28
Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia
Amgen
Phase 2 Completed
NCT01522469 2024-01-30
Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations
Arog Pharmaceuticals, Inc.
Phase 2 Completed
NCT02663622 2024-01-23
MK-7110-002
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2 Completed
NCT00529763 2023-05-08
Dasatinib in Imatinib Resistant/Intolerant Chinese CML (Chronic and Advanced Phase) Subjects
Bristol-Myers Squibb
Phase 2 Completed
NCT05209308 2023-03-16
CORAL
MEI Pharma, Inc.
Phase 2 Withdrawn
NCT03370185 2023-02-28
BRIO
SecuraBio
Phase 2 Withdrawn
NCT04225676 2023-01-30
Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL)
Novartis
Phase 2 Terminated
NCT03873493 2022-12-19
A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia
AbbVie
Phase 2 Completed
NCT05291390 2022-11-29
Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)
Armaceutica, Inc.
Phase 2 Unknown
NCT00042341 2022-05-27
Phase II Study of Clofarabine in Pediatric Acute Lymphoblastic Leukemia (ALL)
Sanofi
Phase 2 Completed
NCT02999633 2022-03-21
ISLAY
Sanofi
Phase 2 Terminated
NCT01810705 2022-02-21
ENFORCE
ERYtech Pharma
Phase 2 Completed
NCT00136903 2022-01-31
Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)
Mesoblast, Ltd.
Phase 2 Completed
NCT01460160 2021-12-08
Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia
Bristol-Myers Squibb
Phase 2 Completed
NCT00644878 2021-08-18
MACS0254
Novartis
Phase 2 Terminated
NCT00449761 2021-07-15
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase
Novartis
Phase 2 Terminated
NCT00012259 2021-06-10
Troxacitabine in Treating Patients With Chronic Myelogenous Leukemia
Takeda
Phase 2 Completed
NCT01844765 2021-04-22
DIALOG
Novartis
Phase 2 Completed
NCT00495079 2021-03-05
Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia
Spectrum Pharmaceuticals, Inc
Phase 2 Completed
NCT00020969 2020-10-05
Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes
CTI BioPharma
Phase 2 Terminated
NCT01369498 2020-07-01
Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis
Gilead Sciences
Phase 2 Completed
NCT01796470 2020-06-02
Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies
Gilead Sciences
Phase 2 Terminated
NCT01207388 2020-02-10
BLAST
Amgen Research (Munich) GmbH
Phase 2 Completed
NCT02538965 2020-01-07
A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Celgene
Phase 2 Completed
NCT00989261 2019-12-11
ACE
Daiichi Sankyo
Phase 2 Completed
NCT01890746 2019-09-11
A Safety and Efficacy Study of Eltrombopag in Subjects With AML
Novartis
Phase 2 Completed
NCT02187783 2019-07-18
SIGNATURE
Novartis
Phase 2 Completed
NCT01214603 2018-11-19
A Study in Participants With Acute Leukemia
Eli Lilly and Company
Phase 2 Completed
NCT00782067 2018-11-15
Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia
Novartis
Phase 2 Completed
NCT02282215 2018-09-27
Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid Leukemia
Cellerant Therapeutics
Phase 2 Completed
NCT00884286 2018-04-25
Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma
PharmaMar
Phase 2 Completed
NCT00391560 2018-03-14
Phase II Study of Perifosine in Patients With Refractory and Relapsed Leukemia
AEterna Zentaris
Phase 2 Completed
NCT00788892 2018-01-12
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Jazz Pharmaceuticals
Phase 2 Completed
NCT00822094 2017-11-24
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Jazz Pharmaceuticals
Phase 2 Completed